Director/PDMR Shareholding

RNS Number : 7371R

Redx Pharma plc

01 July 2020

 

REDX PHARMA PLC

("Redx" or "the Company")

Share Purchases by Directors

Alderley Park, 1 July 2020 - Redx Pharma (AIM:REDX), the drug discovery and development Group focused on cancer and fibrosis, announces that it has been notified that Iain Ross, Non-executive Chairman, has on Tuesday 30 June acquired 215,870 Redx ordinary shares at the following prices: 

Number of Ordinary shares purchased	Price per share (pence)
86 , 881	1 7.25
53,989	18.50
35,000	19.75
40,000	22.50

Following this, Mr Ross will hold 215,870 ordinary shares in the Company, representing 0.11 per cent. of the issued share capital.

The Company also announces that Non-Executive Director Mr Peter Presland has on Tuesday 30 June acquired 118,849 Redx ordinary shares at a price of 25 pence per share. Mr Presland purchased the shares through his self-invested personal pension (SIPP).  Following this, Mr Presland will hold 118,849 ordinary shares in the Company, representing 0.06 per cent of the issued share capital.

-Ends-

For further information, please contact:

Redx Pharma Plc	T: [phone]
Lisa Anson, Chief Executive Officer James Mead, Chief Financial Officer
SPARK Advisory Partners (Nominated Advisor)	T: [phone]
Matt Davis/ Henry Todd
WG Partners LLP (Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting	T: [phone]
Simon Conway/Ciara Martin

About Redx Pharma Plc 

Redx is a UK biotechnology Group whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Iain Ross
2	Reason for notification
a.	Position/Status	Non -Executive Chairman
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Redx Pharma Plc
b.	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 1p each   ISIN: GB00BSNB6S51
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)	86,881 at 17.25 pence per share 53,989 at 18.50 pence per share 35,000 at 19.75 pence per share 40,000 at 22.50 pence per share
d.	Aggregated information - Aggregated Volume - Price	215,870 at 18.94 pence per share
e.	Date of the transaction	30/06/20
f.	Place of the transaction	Outside of trading venue

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Peter Presland
2	Reason for notification
a.	Position/Status	Non-executive Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Redx Pharma Plc
b.	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 1p each   ISIN: GB00BSNB6S51
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)	118,849 25 pence
d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	30/06/20
f.	Place of the transaction	Outside of trading venue

 

END

 

 

DSHUAUARRNUBRAR